Sword Achiever leads GRC in Europe (CIOL)
AchieverPlus provides a single point of access for GRC management for all areas of risk management, compliance management and regulatory affairs.

Zila Releases Preliminary Unaudited Financial Information (Centre Daily Times)
Zila, Inc. (NASDAQ:ZILA) today announced that, based on an unaudited, preliminary assessment, it has achieved positive adjusted EBITDA for its fiscal fourth quarter-ended July 31, 2008. The Company utilizes adjusted EBITDA to determine compliance with a financial covenant in its senior secured convertible notes. The amount is subject to audit adjustments and will be incorporated into the audited ...

PTC124 Shows Promising Activity In Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published In The Lancet (Medical News Today)
New phase 2 data published today in The Lancet show that the investigational oral drug PTC124 demonstrates activity in nonsense-mutation cystic fibrosis (CF). The data show that treatment with PTC124 results in statistically significant improvements in the chloride channel function of patients with nonsense-mutation CF.